NCT03430596View on ClinicalTrials.gov

a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

October 30, 2021

Study Completion Date

December 30, 2021

Conditions
Extrapyramidal Syndrome
Interventions
DRUG

Pramipexole

The dose of pramipexole range from 0.375mg/d to 0.75mg/d , The accurate dose of pramipexole can be adjusted by the patient's condition and tolerance .

DRUG

Trihexyphenidyl hydrochloride

he dose of Antan range from 2 mg/d to 4 mg/d , The accurate dose of pramipexole can be adjusted by the patient's condition and tolerance .

Trial Locations (1)

200030

Shanghai Mental Health Center, Shanghai

All Listed Sponsors
lead

Shanghai Mental Health Center

OTHER

NCT03430596 - a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics | Biotech Hunter | Biotech Hunter